Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events. We sought to develop and validate risk models for predicting absolute risk difference (increased risk or decreased risk) for CVD events and serious adverse events from intensive BP therapy. A secondary aim was to test if the statistical method of elastic net regularization would improve the estimation of risk models for predicting absolute risk difference, as compared to a traditional backwards variable selection approach. METHODS AND FINDINGS: Cox models were derived from SPRINT trial data and validated on ACCORD-BP trial data to estimate risk of CVD events and serious adverse events; the models included terms for intensive BP treatment and heterogeneous response to intensive treatment. The Cox models were then used to estimate the absolute reduction in probability of CVD events (benefit) and absolute increase in probability of serious adverse events (harm) for each individual from intensive treatment. We compared the method of elastic net regularization, which uses repeated internal cross-validation to select variables and estimate coefficients in the presence of collinearity, to a traditional backwards variable selection approach. Data from 9,069 SPRINT participants with complete data on covariates were utilized for model development, and data from 4,498 ACCORD-BP participants with complete data were utilized for model validation. Participants were exposed to intensive (goal systolic pressure < 120 mm Hg) versus standard (<140 mm Hg) treatment. Two composite primary outcome measures were evaluated: (i) CVD events/deaths (myocardial infarction, acute coronary syndrome, stroke, congestive heart failure, or CVD death), and (ii) serious adverse events (hypotension, syncope, electrolyte abnormalities, bradycardia, or acute kidney injury/failure). The model for CVD chosen through elastic net regularization included interaction terms suggesting that older age, black race, higher diastolic BP, and higher lipids were associated with greater CVD risk reduction benefits from intensive treatment, while current smoking was associated with fewer benefits. The model for serious adverse events chosen through elastic net regularization suggested that male sex, current smoking, statin use, elevated creatinine, and higher lipids were associated with greater risk of serious adverse events from intensive treatment. SPRINT participants in the highest predicted benefit subgroup had a number needed to treat (NNT) of 24 to prevent 1 CVD event/death over 5 years (absolute risk reduction [ARR] = 0.042, 95% CI: 0.018, 0.066; P = 0.001), those in the middle predicted benefit subgroup had a NNT of 76 (ARR = 0.013, 95% CI: -0.0001, 0.026; P = 0.053), and those in the lowest subgroup had no significant risk reduction (ARR = 0.006, 95% CI: -0.007, 0.018; P = 0.71). Those in the highest predicted harm subgroup had a number needed to harm (NNH) of 27 to induce 1 serious adverse event (absolute risk increase [ARI] = 0.038, 95% CI: 0.014, 0.061; P = 0.002), those in the middle predicted harm subgroup had a NNH of 41 (ARI = 0.025, 95% CI: 0.012, 0.038; P < 0.001), and those in the lowest subgroup had no significant risk increase (ARI = -0.007, 95% CI: -0.043, 0.030; P = 0.72). In ACCORD-BP, participants in the highest subgroup of predicted benefit had significant absolute CVD risk reduction, but the overall ACCORD-BP participant sample was skewed towards participants with less predicted benefit and more predicted risk than in SPRINT. The models chosen through traditional backwards selection had similar ability to identify absolute risk difference for CVD as the elastic net models, but poorer ability to correctly identify absolute risk difference for serious adverse events. A key limitation of the analysis is the limited sample size of the ACCORD-BP trial, which expanded confidence intervals for ARI among persons with type 2 diabetes. Additionally, it is not possible to mechanistically explain the physiological relationships explaining the heterogeneous treatment effects captured by the models, since the study was an observational secondary data analysis. CONCLUSIONS: We found that predictive models could help identify subgroups of participants in both SPRINT and ACCORD-BP who had lower versus higher ARRs in CVD events/deaths with intensive BP treatment, and participants who had lower versus higher ARIs in serious adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Secondary analyses of ACCORD BP and SPRINT suggest that clinical factors can help determine individuals more likely to bene fi t and less likely to be harmed by intensive blood pressure control (40,41).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“Secondary analyses of ACCORD BP and SPRINT suggest that clinical factors can help identify individuals more likely to benefit from and less likely to be harmed by intensive blood pressure management (46,47).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“Secondary analyses of ACCORD BP and SPRINT suggest that clinical factors can help identify individuals more likely to benefit from and less likely to be harmed by intensive blood pressure management (49,50).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An introduction to ROC analysis
Fawcett, T. (2006) · Pattern Recognition Letters · doi:10.1016/j.patrec.2005.10.010 · Cited by 21,879 · cited 1×
“62] in ACCORD-BP, a meaningfully large difference for serious adverse event discrimination [21,22]) and poorer calibration (slopes of 1.”
BackgroundInformation Theory and an Extension of the Maximum Likelihood Principle
Akaike, H. (1998) · Springer Series in Statistics · doi:10.1007/978-1-4612-1694-0_15 · Cited by 17,781
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Basic principles of ROC analysis
Metz, C. E. (1978) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(78)80014-2 · Cited by 6,026 · cited 1×
“62] in ACCORD-BP, a meaningfully large difference for serious adverse event discrimination [21,22]) and poorer calibration (slopes of 1.”
BackgroundEffects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.639 · Cited by 3,293
Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
Simon, N., Friedman, J., Hastie, T., & Tibshirani, R. (2011) · Journal of Statistical Software · doi:10.18637/jss.v039.i05 · Cited by 2,499 · cited 1×
“Elastic net regularization is a statistical approach designed to select models in the context of collinearity, which produces challenges for older stepwise selection approaches [13,16].”
MethodGlobal Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015
Forouzanfar, M. H., Liu, P., Roth, G. A., Ng, M., Biryukov, S., Marczak, L., Alexander, L., Estep, K., Hassen Abate, K., Akinyemiju, T. F., et al. (2017) · JAMA · doi:10.1001/jama.2016.19043 · Cited by 2,381
Murray, C. J. L., Barber, R. M., Foreman, K. J., Ozgoren, A. A., Abd-Allah, F., Abera, S. F., Aboyans, V., Abraham, J. P., Abubakar, I., Abu-Raddad, L. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61340-x · Cited by 1,964
Self-citation
Cited by
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
“als more likely to benefit and less likely to be harmed by intensive blood pressure control (38,39).”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
“Secondary analyses of ACCORD BP and SPRINT suggest that clinical factors can help determine individualsmore likely to benefit and less likely to be harmed by intensive blood pressure control (37,38).”
Method10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
“Secondary analyses of ACCORD BP and SPRINT suggest that clinical factors can help determine individuals more likely to benefit and less likely to be harmed by intensive blood pressure control (36).”
Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects
Kent, D. M., Steyerberg, E., & van Klaveren, D. (2018) · BMJ · doi:10.1136/bmj.k4245 · Cited by 479
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
Metadata
- Authors
- Basu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A.
- Affiliations
- Harvard University (US)
- University of Michigan (US)
- Stanford University (US)
- Corresponding author
- Basu, Sanjay
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-10-17
- Volume
- 14
- Issue
- 10
- Pages
- e1002410
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC5644999
- OpenAlex
- W2766088180
- Cited by
- 77
- References
- 37
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 2 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 14 · 2019: 15 · 2018: 6 · 2017: 2
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-09-16)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Center on Minority Health and Health Disparities (DP2MD010478)
- National Institute on Minority Health and Health Disparities (U54MD010724)
- National Heart, Lung, and Blood Institute (K08HL121056)
- National Institute of Diabetes and Digestive and Kidney Diseases (P60DK20572)
- Center for Integrated Healthcare, U.S. Department of Veterans Affairs (IIR 11-088, CDA 13-021)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- intensive blood pressure treatment, cardiovascular events, serious adverse events, risk prediction model, elastic net regularization, feature selection, SPRINT trial, number needed to treat, acute kidney injury, hypotension, statin use, serum lipids, age and race differences, model validation, multicollinearity
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antihypertensive Agents, Blood Pressure, Female, Heart Failure, Humans, Hypertension, Male, Middle Aged, Myocardial Infarction, Risk Factors, Proportional Hazards Models, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials. https://app.cochat.ai/papers/10.1371/journal.pmed.1002410
- The paper
- Basu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A. (2017). Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.